BCRX
BioCryst Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.96
−1.29%Margins
Gross margin
23.5%
EBITDA margin
-32.2%
EBIT margin
-33.3%
Net margin
-40.9%
FCF margin
38.0%
84.7%
Return on equity
-69.0%
Return on assets
704.8%
Return on invested capital
1.84x
Asset turnover
$359.9M
Cash from operations
$1.38
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026